Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Cue Biopharma Inc.
Headquarters: Boston, MA, United States of America
Website: https://www.cuebiopharma.com/...
Year Founded: 2014
Status: Public
Industry Sector: HealthTechnology
CEO: Daniel R. Passeri
Number Of Employees: 53
Enterprise Value: $86,973,656
PE Ratio: -1.01
Exchange/Ticker 1: NASDAQ:CUE
Exchange/Ticker 2: N/A
Latest Market Cap: $57,712,100
BioCentury | Jan 23, 2023
Management Tracks
Ryali becomes CFO of Codexis
Plus: Levisetti made CMO at Cue, and updates from Qu and Biocrucible
BioCentury | Mar 18, 2022
Product Development
The IL-2 cancer pipeline remains deep, diverse
There’s still hope for ‘not-alpha’ IL-2 therapies after Nektar’s Ph III failure, with a pipeline full of diverse modalities and MOAs
BioCentury | Jan 28, 2022
Product Development
Jan. 27 Quick Takes: $100M raise is latest step in Zymeworks revival
Plus A first for bioelectronic therapies by Galvani, and updates from Moderna, Cue, Epizyme, Provention, Ziopharm
BioCentury | Dec 16, 2021
Management Tracks
Lambert becomes COO at Myriad
Plus: Remix, Cue and Siranomics
BioCentury | May 28, 2021
Product Development
Amgen’s Lumakras approval marks first of more milestones to come in KRAS story
Amgen is the first to market with a KRAS inhibitor, but there’s still room to expand into new indications, combinations and mutations
BioCentury | Feb 18, 2021
Management Tracks
Day One names York COO, CFO; plus moves at Coherus, Antios, ArsenalBio, Affinia, Artelo and more
After raising a $130 million series B round last week, pediatric oncology company Day One Biopharmaceuticals LLC hired Charles N. York II as COO and CFO. York was CFO and head of corporate development
Items per page:
1 - 10 of 20